Group One Trading’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$122 Hold
100
– – ﹤0.01% 7367
2026
Q2
$107 Hold
100
– – ﹤0.01% 7403
2026
Q1
$375 Hold
100
– – ﹤0.01% 7345
2025
Q4
$353 Buy
+100
New +$406 ﹤0.01% 7845
2024
Q2
– Sell
-4,787
Closed -$19K – 6621
2024
Q1
$21.5K Buy
4,787
+2,555
+114% +$9.42K ﹤0.01% 5363
2023
Q4
$3.7K Hold
2,232
– – ﹤0.01% 6626
2023
Q3
$2K Buy
2,232
+2,137
+2,249% +$2.84K ﹤0.01% 7045
2023
Q2
$204 Hold
95
– – ﹤0.01% 7468
2023
Q1
$185 Sell
95
-805
-89% -$2.97K ﹤0.01% 6997
2022
Q4
$3.46K Hold
900
– – ﹤0.01% 6488
2022
Q3
$4K Buy
+900
New +$6.52K ﹤0.01% 6884
2022
Q1
– Sell
-100
Closed -$1.59K – 7950
2021
Q4
$2K Buy
+100
New +$2.41K ﹤0.01% 7852
2021
Q3
– Sell
-200
Closed -$5.12K – 8096
2021
Q2
$5K Hold
200
– – ﹤0.01% 7738
2021
Q1
$5K Sell
200
-200
-50% -$5.79K ﹤0.01% 7224
2020
Q4
$13K Buy
+400
New +$13.1K ﹤0.01% 5685

Other funds holding ADCT

Group One Trading's ADCT Position: Q3 2026 in Review

Group One Trading held its ADC Therapeutics (ADCT) position steady in Q3 2026 at 100 shares worth $122. The position accounts for ﹤0.01% of the portfolio, ranked #7367.

Group One Trading first reported a position in ADCT in Q4 2020 and has held it in 15 quarters since. The position peaked at $21.5K in Q1 2024. 110 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • Group One Trading held 100 shares of ADC Therapeutics worth $122 as of Q3 2026.
  • Group One Trading left its ADC Therapeutics share count unchanged in Q3 2026.
  • ADC Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #7367 holding.
  • Group One Trading first reported a position in ADC Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Group One Trading's ADC Therapeutics position peaked at $21.5K in Q1 2024.
  • 110 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.